News & Events about Vaxxinity Inc.
Vaxxinity, Inc. (NASDAQ:VAXX Get Rating) major shareholder Movers Lab Fund I. Lp Prime sold 405,217 shares of Vaxxinity stock in a transaction that occurred on Monday, January 23rd. The stock was sold at an average price of $3.35, for a total transaction of $1,357,476.95. Following the ...
DALLAS, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that Mei Mei Hu, Chief Executive Officer of Vaxxinity, will present an update on the Company and its pipeline at the 41st ...
Vaxxinity, Inc. (NASDAQ:VAXX Get Rating) major shareholder Movers Lab Fund I. Lp Prime sold 270,964 shares of the businesss stock in a transaction on Thursday, December 1st. The stock was sold at an average price of $2.97, for a total transaction of $804,763.08. Following the ...
Globe Newswire
2 months ago
Vaxxinitys next-generation COVID-19 booster candidate UB-612 achieves primary and key secondary immunogenicity endpoints in a pivotal head-to-head heterologous booster trial against three authorized vaccine platforms: mRNA (Pfizer-BioNTechs BNT162b2), adenovirus vector (AstraZenecas ChAdOx1-S), and ...
Globe Newswire
5 months ago
UB-612 Phase 3 COVID-19 Heterologous Boost Trial on Track for Topline Readout in Fourth Quarter of 2022 UB-312 Phase 1 Part B Trial for Parkinsons Completes Last Patient Last Dose, and Remains on Track to Complete an End-of-Treatment Analysis in the Second Half of 2022 Advanced UB-313 Anti-CGRP ...